Triple-negative breast cancer has entered a new era.

At ESMO 2025, TRO-Breast02 and ASCENT-03 delivered practice-shifting data — from rapid progressors to PD-L1–defined pathways and the growing role of TROP2-targeted ADCs.

Dr. Neil Iyengar and Dr. Erika Hamilton break down trial design differences, crossover implications, toxicity management, and how these results will shape first-line treatment decisions for TNBC.

#BreastCancer #TNBC #TripleNegativeBreastCancer #TROP2 #ADCs #TDXd #SacituzumabGovitecan #ASCENT03 #TROB02 #ESMO2025 #Oncology #CancerResearch #CHM

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

The landscape of HER2+ and HER2-low breast cancer is shifting fast — and DB-05 and DB-11 are at the center of it.

In this deep-dive from ESMO 2025, Dr. Gregory Vidal and Dr. Erika Hamilton break down what the latest T-DXd data means for real-world practice, how ILD should be monitored, and why sequencing matters more than ever.

#BreastCancer #HER2 #HER2Low #TDXd #TrastuzumabDeruxtecan #ESMO2025 #DB05 #DB11 #OncologyEducation #CancerResearch #MedicalOncology #CHM

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

At ESMO Berlin, Dr. Mark Pegram and Dr. Ana Garrido-Castro break down breakthrough data shaping the new standard for first-line metastatic triple-negative breast cancer (TNBC).

Together, they unpack results from ASCENT-03 and TROPION-Breast02, where Trop-2 antibody-drug conjugates demonstrated significant improvements in response rates, PFS, and — in one study — overall survival.

Drs. Pegram and Garrido-Castro explore:

• Why Trop-2 ADCs may replace chemotherapy in PD-L1–negative TNBC

• Key differences in trial design, patient selection, and endpoints

• Real-world decision-making based on toxicity, dosing schedules, and prophylaxis

• How HR-low disease, BRCA/PALB2 status, and CNS involvement factor into treatment strategy

A must-listen for clinicians navigating the fast-evolving landscape of metastatic TNBC and the rise of ADC-driven precision therapy.

#BreastCancer #TNBC #TripleNegativeBreastCancer #ESMO2025 #OncologyPodcast #Trop2 #ADCtherapy #CancerResearch #ClinicalOncology #BreastOncology #PrecisionOncology #CHM

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media